Tibial nerve stimulation to inhibit the micturition reflex by an implantable wireless driver microstimulator in cats

Xing Li, MDa,b,c, Li-Min Liao, MD, PhDa,b,c,*, Guo-Qing Chen, MD, PhDa,b,c, Zhao-Xia Wang, MDa,b,c, Tian-Ji Lu, MSCa,b,c, Han Deng, MSCa,b,c, Gerald-E Loeb, MD, PhDd

Abstract

Background: Traditional tibial nerve stimulation (TNS) has been used to treat overactive bladder syndrome (OAB), but there are some shortcomings. Thus, a novel alternative is needed for the treatment of OAB. The study investigated the effects of a new type of tibial nerve microstimulator on the micturition reflex in cats.

Methods: An implantable wireless driver microstimulator was implanted around the tibial nerve in 9 α-chloralose anesthetized cats. Cystometry was performed by infusing 0.9% normal saline (NS) or 0.25% acetic acid (AA) through a urethral catheter. Multiple cystometrograms were performed before, during, and after TNS to determine the inhibitory effect of the microstimulator on the micturition reflex.

Results: TNS at 2 threshold (T) intensity significantly increased the bladder capacity (BC) during NS infusion. Bladder overactivity was irritated by the intravesical infusion of 0.25% AA, which significantly reduced the BC compared with the NS infusion. TNS at 2 T intensity suppressed AA-induced bladder overactivity and significantly increased the BC compared with the AA control.

Conclusion: The implantable wireless driver tibial nerve microstimulator appears to be effective in inhibiting the micturition reflex during physiologic and pathologic conditions. The implantable wireless driver tibial nerve microstimulator could be used to treat OAB.

Abbreviations: AA = acetic acid, BC = bladder capacity, CMGs = cystometrograms, NS = normal saline, OAB = overactive bladder syndrome, RF = radiofrequency, T = threshold, TNS = tibial nerve stimulation.

Keywords: cat, implantable, microstimulator, micturition reflex, tibial nerve stimulation

1. Introduction

Overactive bladder syndrome (OAB) is defined by the International Continence Society as “urgency, with or without urge incontinence, usually with frequency and nocturia in the absence of proven infection or other obvious pathology.”[1] The prevalence of OAB in adult ranges from 10.2% to 17.4% in males and 7.7% to 31.3% in females.[2] OAB is a common urologic disorder which seriously impacts the quality of life and imposes a substantial economic burden on the healthcare system. Overactive bladder syndrome, usually with frequency and nocturia in the absence of proven infection or other obvious pathology. Thus, a novel alternative is needed for the treatment of OAB. The study investigated the effects of a new type of tibial nerve microstimulator on the micturition reflex in cats.

Methods: An implantable wireless driver microstimulator was implanted around the tibial nerve in 9 α-chloralose anesthetized cats. Cystometry was performed by infusing 0.9% normal saline (NS) or 0.25% acetic acid (AA) through a urethral catheter. Multiple cystometrograms were performed before, during, and after TNS to determine the inhibitory effect of the microstimulator on the micturition reflex.

Results: TNS at 2 threshold (T) intensity significantly increased the bladder capacity (BC) during NS infusion. Bladder overactivity was irritated by the intravesical infusion of 0.25% AA, which significantly reduced the BC compared with the NS infusion. TNS at 2 T intensity suppressed AA-induced bladder overactivity and significantly increased the BC compared with the AA control.

Conclusion: The implantable wireless driver tibial nerve microstimulator appears to be effective in inhibiting the micturition reflex during physiologic and pathologic conditions. The implantable wireless driver tibial nerve microstimulator could be used to treat OAB.

Abbreviations: AA = acetic acid, BC = bladder capacity, CMGs = cystometrograms, NS = normal saline, OAB = overactive bladder syndrome, RF = radiofrequency, T = threshold, TNS = tibial nerve stimulation.

Keywords: cat, implantable, microstimulator, micturition reflex, tibial nerve stimulation

2. Methods

2.1. Device introduction

The NuStim device consists of 3 subsystems (the stimulator, the radiofrequency [RF] cushion, and the android pad; Fig. 1). The stimulator has a cylindrical shape with 2 leads on each side (3 mm in diameter × 10 mm in length; Fig. 2). The stimulator receives RF electromagnetic pulses from an external machine, the RF cushion (Fig. 3), and transforms the RF electromagnetic pulses into current pulses. The stimulation parameters are as follows: 0 to 15 V, 2 to 20 Hz pulse rate, and 200 ms pulse width. The stimulation parameters can be adjusted immediately during the treatment using a remote control [an app from an android pad]. The current pulse generated by the stimulator is a biphasic, asymmetric exponential pulse.
2.2. Experimental setup

Experiments were conducted in 9 cats (5 males and 4 females, 2.5–3.5 kg, 6–12 months old, domestic shorthairs) under α-chloralose anesthesia (65 mg/kg intravenously) after induction with isoflurane (2%–3% in oxygen). A tube was inserted to maintain airway access after a tracheotomy. Heart rate, blood oxygen level, and systemic blood pressure were monitored throughout the experiment. Fluid was administered via the cephalic vein. Body temperature was maintained with a heating pad. The Animal Care and Use Committee at the Capital Medical University approved all protocols involving the use of animals in this study (AEEI-2016-041).

Cats underwent implantation in the supine position after disinfection of the right hindlimb. A 2- to 3-cm incision was made on the medial side of the hindlimb above the ankle. The tibial nerve was exposed. Then, the stimulator was placed near the neurovascular bundle parallel to the tibial nerve and its cathode perpendicular to the cushion. During the procedure, the stimulator was activated to confirm function and placement. Toe movement was observed when the stimulator was properly positioned. The stimulator was fixed by a ligature around the neurovascular bundle if proper placement was confirmed and the wound was closed.

The ureters were isolated via an abdominal incision. The ureters were cut and drained externally. The bladder was inserted via a double lumen catheter through the urethra. The catheter was then secured by a ligature around the urethra. One lumen of the catheter was used to infuse the bladder with either 0.9% normal saline (NS) or 0.25% AA at a rate of 1 to 2 mL/min after connecting to a pump. The other lumen was connected to a pressure transducer to measure the bladder pressure. After completing the preparation work, stimulation was applied.

2.3. Stimulation protocol

Biphasic exponential pulses (200-μs pulse width, 6-Hz frequency) were delivered to the tibial nerve. By gradually increasing the stimulation intensity, the intensity threshold (T) inducing toe movement was determined. The BC was used to test the inhibitory effect of the stimulator. After the appearance of the first large-amplitude (>30 cmH2O) bladder contraction, the bladder infusion with NS or AA was stopped. After emptying the bladder, 2 or 3 cystometrograms (CMGs) with NS were performed without stimulation to obtain the control BC and assess the reproducibility. After the BC was stabilized, TNS (frequency, 6 Hz; intensity, 1–2 T) was applied during 2 sequential CMGs. Another CMG without stimulation was performed in the end. Second, after emptying the bladder, 0.25% AA was infused into the bladder to irritate and induce bladder overactivity during 3 to 5 CMGs (1 hour). After the BC stabilized, TNS (frequency, 6 Hz; intensity, 1–2 T) was applied again during 2 sequential CMGs. Another CMG without stimulation was performed in the end. The bladder was emptied after each CMG, and a 10-minute rest period was permitted between successive CMGs to allow the distended bladder to recover.

2.4. Statistical analysis

The Statistical Package for the Social Sciences (SPSS) version 19.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. The level of significance was 0.05. To compare the repeated CMG recordings, the BCs were normalized to the measurement of
the first control CMG during the NS or AA infusion. Repeated
measurements of the same animal under the same CMG
conditions were averaged. All summary data are expressed as
the mean ± Standard error (SE). Statistical signiﬁcance was
detected by one-way Analysis of Variance (ANOVA) followed
by Bonferroni posttests or Kruskal–Wallis test followed by
Tamhane posttests.

3. Results
All of the cats were implanted successfully. There was no obvious
bleeding or edema observed during the surgical procedure and
stimulation process.

During infusion with NS, the large-amplitude (>30 cmH2O)
and long-duration (>20 s) bladder contractions were
induced when the BC reached the micturition volume (the ﬁrst
traces in Figs. 4 and 5). Compared with the baseline level (103.3
± 8.5 mL), TNS at 1 T intensity did not signiﬁcantly increase the
BC (109.0 ± 19.7 mL; P = 1.00). TNS at 2 T intensity signiﬁcantly
increased the BC (147.1 ± 29.1 mL) compared to the baseline
level (P = 0.03; Fig. 4). Irritation of the bladder with 0.25% AA-
induced bladder overactivity and signiﬁcantly reduced the BC
(54.9 ± 18.4 mL) compared to NS infusion (P < 0.001). When
TNS was applied at 1 T intensity, AA-induced bladder
overactivity was not suppressed nor was the BC signiﬁcantly
increased (66.5 ± 20.1 mL; P = 0.22) compared to the AA control
level. TNS at 2 T intensity reduced AA-induced bladder
overactivity and signiﬁcantly increased BC (87.0 ± 28.1 mL)
compared to the AA control (P = 0.01); the BC did not return
to the NS control level (P = 0.88; Fig. 5). During the experiment,
the CMGs were stable because the BC returned to the initial level
after infusion of NS and AA when the stimulation was stopped
(the fourth and ﬁfth traces in Figs. 4 and 5).

4. Discussion
The tibial nerve is a mixed sensory and motor nerve containing
L4–S3 ﬁbers that originate from the same spinal segments as the
innervations to the bladder and pelvic ﬂoor. The ankle region
of TNS is close to the Sanyinjiao used in Chinese acupuncture.[6]
The technique has been used to treat lower urinary tract
dysfunction, such as urgency, frequency, enuresis, incontinence,
and retention of urine.[7] Although the mechanism underlying
TNS is not clear, a number of studies have been conducted to
prove the efﬁcacy of TNS in treating patients with OAB,
especially for patients who are refractory to conservative
treatments or experience intolerable side effects of drug
therapy.[8,9]

Urgent® PC (Uroplasty Ltd., Manchester, UK) is an FDA-
approved, minimally invasive, ofﬁce-based neuromodulation
system designed to deliver retrograde stimulation to the sacral
erve plexus through percutaneous electrical stimulation of the
posterior tibial nerve.[10] Urgent PC has been shown to be safe
with statistically signiﬁcant improvements in patient assessment
of OAB, and with objective efﬁcacy comparable to pharmaco-
therapy.[11] However, the patients need a temporary insertion of
a 34 gauge needle electrode, slightly cephalad to the medial
malleolus each time, which may lead to bleeding, pain, and
uncomfortable feelings. The procedure must be performed by a
professional.

To overcome the disadvantage of Urgent PC, adhesive skin
surface electrodes have been used instead of needle electrodes
to treat OAB.[12,13] Although adhesive skin surface electrode
therapy is noninvasive and easily managed by patients, it may be
less effective than percutaneous TNS, in part because of the
indirect nerve stimulation.\textsuperscript{[14]} In addition, adhesive skin surface electrode therapy also needs a medical professional to identify the proper position of the surface electrode, just as for needle electrodes.

In 2006, a study reported an implant-driven TNS device (Urgent-SQ: CystoMedix Inc., Anoka, MN) in the treatment of refractory OAB.\textsuperscript{[15]} The device consists of an external electromagnetic pulse generator with RF transmission capability and an internal electromagnetic pulse receiver. Urgent-SQ has a similar working principle as the device used in this study; however, the external stimulator has to be placed directly on the skin with a cuff around the medial malleolus to activate the internal body and the implant is relatively long (approximately 4 cm). The implantation requires a 5- to 7-cm incision approximately 5 cm above the medial malleolus and parallel to the tibia under spinal or general anesthesia. Thus, this technique has not been widely used.

In this study, we performed the TNS procedure with an implantable wireless driver microstimulator (NuStim). NuStim consists of 3 subsystems (the implantable microstimulator, the RF cushion, and the android pad). The stimulator receives RF electromagnetic pulses from the RF cushion and transforms the RF electromagnetic pulses into current pulses. The stimulation parameters can be adjusted by a remote control (an app from an android pad). Even though we also implanted the stimulator via an open surgical procedure in this study, it can be performed in a fully percutaneous and simplified way in patients in the future as the implantation for the tined lead in the InterStim Therapy procedure (Medtronic, Minneapolis, Minn, US) because this microstimulator is only 3 mm in diameter and 10 mm in length (Fig. 2). The insertion surgical kit has now been produced and will be used for clinical trials. The other advantage of our microstimulator is that it does not require an integrated battery. The microstimulator receives RF electromagnetic pulses from the RF cushion and transforms the RF electromagnetic pulses into current pulses. Thus, the patients do not need to replace the stimulator when the battery is depleted, as with the InterStim.

In this study, we investigated the effects of acute TNS delivered by a microstimulator on the micturition reflex in normal and OAB cats, which revealed that TNS with the NuStim device implanted in the tibial nerve in cats is effective in not only inhibiting bladder activity induced by intravesical infusion of NS, but also suppressing bladder overactivity induced by intravesical infusion of AA. TNS at 2 T intensity significantly increased BC compared to the baseline level during NS infusion (\(P = 0.03\); Fig. 4) while suppressing AA-induced bladder overactivity and significantly increasing BC compared to the AA control (\(P = 0.01\); Fig. 5). Our study showed similar results performed by direct TNS via the cuff electrode in cats\textsuperscript{[14,15]} and appears to be practical in treating patients with OAB via the implanted stimulator in the future.

OAB treatment needs repeated stimulation sessions long term or lifelong. This limits the use of traditional TNS. With the production of an insertion kit and wearable external electromagnetic pulse generator, the NuStim device is a minimally invasive neuromodulation technique for OAB patients. The NuStim is placed closer to the tibial nerve, which could produce a more effective stimulation. Patients can do activities, such as reading and watching TV, during the treatment. As a self-administered therapy without professional supervision, it can be easily taught to patients or their families and could be applied at home; however, we only investigated the acute effect of the NuStim device in this study and there was a lack of information on long-term therapy. Moreover, although there were no obvious side effects (i.e., bleeding or edema) in this study, it was still unknown whether it could induce pain, infection, and other complications or not. In addition, the biocompatibility of the implants needed to be determined during chronic use.

In conclusion, this study has demonstrated that TNS by an implantable wireless driver microstimulator (NuStim) is effective in inhibiting the micturition reflex during physiologic and pathologic conditions. Moreover, improved BC, which was observed in this study, is an encouraging finding that can be used as a potential treatment modality in the clinical practice of overactive bladder.

**Acknowledgments**

The authors would like to thank the Natural Science Foundation of China and Beijing Natural Science Foundation for financially supporting this research. They also would like to thank Fangping Li, Fangxi Li, and Xue-Chen Huang for the supports for this study and the valuable discussion and suggestions.

**References**

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49.

2. Abrams P, Arriberti W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28:287.

3. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572–80.

4. Tai C, Larson JA, Ogagan PD, et al. Differential role of opioid receptors in tibial nerve inhibition of nociceptive and nonnociceptive bladder reflexes in cats. Am J Physiol Renal Physiol 2012;302:F1090–7.

5. Tai C, Chen M, Shen B, et al. Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats. J Urol 2011;186:326–30.

6. McGuire EJ, Zhang SC, Horwinski ER, et al. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol 1983;129:78–9.

7. Congregado Ruiz B, Pena Outeiriño XM, Campoy Martínez P, et al. Peripheral afferent nerve stimulation for treatment of lower urinary tract irritative symptoms. Eur Urol 2004;45:65–9.

8. Peters KM, Carrico DJ, Wooldridge LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013;189:2194–201.

9. Manriquez V, Guzmán R, Naser M, et al. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients: A prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 2016;196:6–10.

10. van Balken MR. Percutaneous tibial nerve stimulation: the Urgent PC device. Expert Rev Med Devices 2007;4:693–8.

11. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009;182:1055–61.

12. de Sae M, Raibaut P, Gellien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 2011;30:306–11.

13. Chen G, Liao L, Li Y. The possible role of percutaneous tibial nerve stimulation using adhesive skin surface electrodes in patients with neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol 2015;47:451–5.

14. van der Pal F, van Balken MR, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 2006;97:547–50.

15. van der Pal F, van Balken MR, Heesakkers JP, et al. Implant-driven tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: 12-month follow-up. Neuromodulation 2006;9:163–71.